FOLD - Amicus Therapeutics, Inc.
| Previous Close | 16.00 |
| Open | 15.93 |
| Bid | 15.96 x 900 |
| Ask | 15.98 x 200 |
| Day's Range | 15.78 - 16.01 |
| 52 Week Range | 11.44 - 17.62 |
| Volume | 230,066 |
| Avg. Volume | 2,235,604 |
| Market Cap | 3.012B |
| Beta | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE•24 days ago
Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.
- ACCESSWIRE•26 days ago
Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...
- GlobeNewswire•27 days ago
Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease
Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for AT-GAA for Pompe disease following guidance from regulators in the European Union as well as guidance on manufacturing and bio-comparability from German regulatory authorities (BfArM). 2) to discuss whether Amicus may pursue a pathway for AT-GAA that includes a conditional marketing approval (CMA) application in Europe. Amicus has concluded this series of interactions and has now received written guidance from the SAWP.
- GlobeNewswire•last month
Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors
Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the election and appointment of the Company’s President and Chief Operating Officer Bradley L. Campbell to its Board of Directors, effective immediately. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to announce Bradley’s appointment to the Board.
- GlobeNewswire•2 months ago
Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
CRANBURY, N.J., June 01, 2018-- Amicus Therapeutics, Inc. announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming ...
- GlobeNewswire•2 months ago
Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan
Amicus Therapeutics (FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold® capsules 123mg (migalastat) for treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. Galafold is the first and only oral precision medicine for Fabry disease in Japan. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “The launch of Galafold in Japan, less than one year after our J-NDA submission, provides a significant opportunity for us to deliver this oral and differentiated precision medicine to amenable Fabry patients living in Japan.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Amicus Therapeutics and Insmed
NEW YORK, NY / ACCESSWIRE / May 25, 2018 / U.S. markets were weighed down by the energy sector on Thursday as U.S. crude oil prices closed lower for the third consecutive session. However, major indexes ...
- ACCESSWIRE•2 months ago
Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks
Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Puma Biotechnology and Amicus Therapeutics
NEW YORK, NY / ACCESSWIRE / May 16, 2018 / U.S. markets slumped Tuesday, with the Dow Jones breaking an 8-day win streak, as interest rates surged to new highs. The Dow Jones Industrial Average declined 0.78 percent to close at 24,706.41, while the S&P 500 Index fell 0.68 percent to close at 2,711.45.
- GlobeNewswire•2 months ago
Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
CRANBURY, N.J., May 09, 2018-- Amicus Therapeutics today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 ...
- GlobeNewswire•2 months ago
Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
Continued Global Galafold ® Adoption and Expansion– Reaffirms FY18 Revenue Guidance of $75 M- $85 M at Top End of Range. Significant Momentum with Pompe Clinical, Regulatory and Manufacturing Activities- ...
- GlobeNewswire•3 months ago
Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
CRANBURY, N.J., April 26, 2018-- Amicus Therapeutics today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ...
- ACCESSWIRE•5 months ago
Today’s Research Reports on Trending Tickers: Gilead Sciences and Amicus Therapeutics
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / U.S. markets closed lower Wednesday to end February in the red, with the Dow Jones and S&P 500 breaking its longest monthly gain streak since 1959. The Dow Jones ...
- ACCESSWIRE•5 months ago
Amicus Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018, at 8:30 AM ...